National Health Commission of the PRC recently convened a meeting in Beijing to outline ten practical initiatives for public service by 2026.

Adaptive Biotechnologies said last week that its new subsidiary Digital Biotechnologies has held an initial closing of its Series A preferred stock financing and expects to raise up to $15 million in the round.

Mdxhealth and the University of Oxford will test whether the firm's Genomic Prostate Score (GPS) assay can predict disease progression and treatment outcomes in prostate cancer patients, the company said Tuesday.

2. Current Conditions of Blood Coagulation Analyzers and Reagents in China As indicated by the release of the China Cardiovascular Health and Disease Report 2024, the current number of cardiovascular pat..

Original from: GlobeNewswire Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the f..

Corewell Health and Quest Diagnostics (NYSE: DGX) today announced the completion of the previously announced transaction to establish a laboratory services joint venture to expand access to innovative, quality and affordable laboratory services in Michigan.

Roche Diagnostics’ VENTANA MMR RxDx Panel CDx Approved in China Roche Diagnostics’ VENTANA MMR RxDx Panel companion diagnostic (CDx) reagent has officially obtained approval of NMPA. As ..

On 17 December 2025, the World Health Organization (WHO) announced the prequalification of two rapid antigen diagnostic tests (Ag-RDT) for SARS-CoV-2, the virus that causes COVID-19. The two tests are the SD Biosensor STANDARD Q COVID-19 Ag Test and the ACON Biotech Flowflex SARS-CoV-2 Antigen Rapid Test (Self-Testing). This marks the first time that rapid antigen tests for SARS-CoV-2 have achieved WHO prequalification.

Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary LEADS® drug discovery platform, announced today it has been awarded a research grant from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH), to further advance its data-driven drug discovery capabilities.

Biobeat Technologies, Ltd., developer of the first FDA-cleared, 24-hour ambulatory blood pressure monitoring (ABPM) system that is a patch-worn, cuff-less solution for diagnosis and treatment of hypertension, announced today the closing of a $50 million Series B equity financing.

Blood Coagulation Analyzer and Reagents 1. Overview of Domestic Blood Coagulation Market Conventional thrombosis and hemostasis diagnostic applications are mainly concentrated on screening for bleeding dis..

Italian in vitro diagnostics firm Diasorin said on Sunday that the US Food and Drug Administration has issued 510(k) clearance and CLIA-waived the firm's first assay for use on the Liaison Nes platform.

The EU's Unified Patent Court last week ruled in favor of Myriad Genetics in its patent dispute with South Korean firm GXD-Bio.

Applied BioCode said on Monday that is has submitted a new nucleic acid extraction claim for its BioCode Respiratory Pathogen Panel (RPP) to the US Food and Drug Administration, with the goal of expanding use of the panel by clinical laboratories.

Following decades of cumulative efforts, a number of infectious disease tests and technologies broke new ground in 2025, hinting at rapid advances in the development of new systems and assays.

Chinese molecular diagnostics and precision medicine firm GenePlus Technology said on Sunday that it has filed for an initial public offering on the Hong Kong Stock Exchange.

MGI Tech Partners with Cenglang Biotechnology to Deepen Expansion in the Asia-Pacific Region On December 26th, Beijing Cenglang Biotechnology Co.,Ltd. and MGI Tech reached a strategic cooperation agreemen..

Chinese molecular diagnostics and precision medicine firm GenePlus Technology said on Sunday that it has filed for an initial public offering on the Hong Kong Stock Exchange.

Singlera Genomics said on Tuesday that it has entered into a research and distribution agreement with EU-based international medical company Pure Medical for its cell-free DNA detection products

Zydus Lifesciences said on Friday that it has signed an agreement to exclusively commercialize a trio of Myriad Genetics cancer tests in India.